Literature DB >> 21135090

Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells.

Amandine Chaix1, Sophie Lopez, Edwige Voisset, Laurent Gros, Patrice Dubreuil, Paulo De Sepulveda.   

Abstract

Mutations in the c-kit gene occur in the vast majority of mastocytosis. In adult patients as well as in the cell line derived from mast cell neoplasms, the mutations occur almost exclusively at amino acid 816 within the kinase domain of KIT. Among the downstream effectors of KIT signaling, STAT3 and STAT5 have been shown to be critical for cell proliferation elicited by the KIT-Asp(816) mutant protein. However, little is known about the mechanisms of activation of STAT proteins. In this study, we identify and clarify the contribution of various STAT kinases in two widely used neoplastic mast cell lines, P815 and HMC-1. We show that STAT1, -3, and -5 proteins are activated downstream of the KIT-Asp(816) mutant. All three STAT proteins are located in the nucleus and are phosphorylated on serine residues. KIT-Asp(816) mutant can directly phosphorylate STATs on the activation-specific tyrosine residues in vitro. However, within cells, SRC family kinases and JAKs diversely contribute to tyrosine phosphorylation of STAT proteins downstream of the KIT mutant. Using a panel of inhibitors, we provide evidence for the implication or exclusion of serine/threonine kinases as responsible for serine phosphorylation of STAT1, -3, and -5 in the two cell lines. Finally, we show that only STAT5 is transcriptionally active in these cells. This suggests that the contribution of STAT1 and STAT3 downstream of KIT mutant is independent of their transcription factor function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21135090      PMCID: PMC3057865          DOI: 10.1074/jbc.M110.182642

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

1.  Protein kinase C-delta (PKC-delta ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727.

Authors:  Shahab Uddin; Antonella Sassano; Dilip K Deb; Amit Verma; Beata Majchrzak; Arshad Rahman; Asrar B Malik; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2002-02-11       Impact factor: 5.157

Review 2.  Stats: transcriptional control and biological impact.

Authors:  David E Levy; J E Darnell
Journal:  Nat Rev Mol Cell Biol       Date:  2002-09       Impact factor: 94.444

Review 3.  JAK-STAT signaling: from interferons to cytokines.

Authors:  Christian Schindler; David E Levy; Thomas Decker
Journal:  J Biol Chem       Date:  2007-05-14       Impact factor: 5.157

4.  Platelet-derived growth factor (PDGF)-induced activation of signal transducer and activator of transcription (Stat) 5 is mediated by PDGF beta-receptor and is not dependent on c-src, fyn, jak1 or jak2 kinases.

Authors:  K Paukku; S Valgeirsdóttir; P Saharinen; M Bergman; C H Heldin; O Silvennoinen
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

5.  Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581.

Authors:  M H Tomasson; D W Sternberg; I R Williams; M Carroll; D Cain; J C Aster; R L Ilaria; R A Van Etten; D G Gilliland
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

6.  Jak2 acts as both a STAT1 kinase and as a molecular bridge linking STAT1 to the angiotensin II AT1 receptor.

Authors:  M S Ali; P P Sayeski; K E Bernstein
Journal:  J Biol Chem       Date:  2000-05-19       Impact factor: 5.157

Review 7.  STATs in oncogenesis.

Authors:  T Bowman; R Garcia; J Turkson; R Jove
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

8.  Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells.

Authors:  Z Q Ning; J Li; R J Arceci
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

Review 9.  Serine phosphorylation of STATs.

Authors:  T Decker; P Kovarik
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

10.  The tyrosine kinase FES is an essential effector of KITD816V proliferation signal.

Authors:  Edwige Voisset; Sophie Lopez; Patrice Dubreuil; Paulo De Sepulveda
Journal:  Blood       Date:  2007-06-26       Impact factor: 22.113

View more
  30 in total

1.  Novel mechanism for Fc{epsilon}RI-mediated signal transducer and activator of transcription 5 (STAT5) tyrosine phosphorylation and the selective influence of STAT5B over mast cell cytokine production.

Authors:  Nicholas A Pullen; Brian O Barnstein; Yves T Falanga; Zhengqi Wang; Ryo Suzuki; Tenchee D Lama Tamang; Michele C Khurana; Emily A Harry; Petr Draber; Kevin D Bunting; Kazuya Mizuno; Bridget S Wilson; John J Ryan
Journal:  J Biol Chem       Date:  2011-11-30       Impact factor: 5.157

2.  The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.

Authors:  S Agarwal; J U Kazi; S Mohlin; S Påhlman; L Rönnstrand
Journal:  Oncogene       Date:  2014-12-01       Impact factor: 9.867

3.  Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor.

Authors:  Benedikt Bosbach; Ferdinand Rossi; Yasemin Yozgat; Jennifer Loo; Jennifer Q Zhang; Georgina Berrozpe; Katherine Warpinski; Imke Ehlers; Darren Veach; Andrew Kwok; Katia Manova; Cristina R Antonescu; Ronald P DeMatteo; Peter Besmer
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-18       Impact factor: 11.205

Review 4.  Update on diagnosis and treatment of mastocytosis.

Authors:  Knut Brockow; Johannes Ring
Journal:  Curr Allergy Asthma Rep       Date:  2011-08       Impact factor: 4.806

5.  Phenotypes of STAT3 gain-of-function variant related to disruptive regulation of CXCL8/STAT3, KIT/STAT3, and IL-2/CD25/Treg axes.

Authors:  Lia Furlaneto Marega; Janine Schincariol Sabino; Marcus Vinicius Pedroni; Marcelo Teocchi; Carolina Lanaro; Dulcinéia Martins de Albuquerque; Irene Pereira Dos Santos; Fernando Ferreira Costa; Maria Marluce Dos Santos Vilela
Journal:  Immunol Res       Date:  2021-08-14       Impact factor: 2.829

Review 6.  Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.

Authors:  Siham Bibi; Melis Dilara Arslanhan; Florent Langenfeld; Sylvie Jeanningros; Sabine Cerny-Reiterer; Emir Hadzijusufovic; Luba Tchertanov; Richard Moriggl; Peter Valent; Michel Arock
Journal:  Haematologica       Date:  2014-03       Impact factor: 9.941

7.  Towards a quantitative understanding of the MITF-PIAS3-STAT3 connection.

Authors:  Josef Thingnes; Timothy J Lavelle; Arne B Gjuvsland; Stig W Omholt; Eivind Hovig
Journal:  BMC Syst Biol       Date:  2012-02-08

8.  Oncogenic KIT Modulates Type I IFN-Mediated Antitumor Immunity in GIST.

Authors:  Mengyuan Liu; Mark S Etherington; Andrew Hanna; Benjamin D Medina; Gerardo A Vitiello; Timothy G Bowler; Nesteene J Param; Lillian Levin; Ferdinand Rossi; Ronald P DeMatteo
Journal:  Cancer Immunol Res       Date:  2021-03-01       Impact factor: 12.020

9.  TET2 regulates immune tolerance in chronically activated mast cells.

Authors:  Riccardo Rigo; Rabie Chelbi; Julie Agopian; Sebastien Letard; Aurélien Griffon; Hussein Ghamlouch; Julien Vernerey; Vasileios Ladopoulos; Edwige Voisset; Paulo De Sepulveda; Geoffrey Guittard; Jacques A Nunès; Ghislain Bidaut; Berthold Göttgens; Michael Weber; Olivier A Bernard; Patrice Dubreuil; Erinn Soucie
Journal:  JCI Insight       Date:  2022-04-08

Review 10.  Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder.

Authors:  Anindya Chatterjee; Joydeep Ghosh; Reuben Kapur
Journal:  Oncotarget       Date:  2015-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.